MedTrace Logo

A Phase III Trial To Evaluate The Efficacy And Safety Of MC2-01 Cream Compared To CAL/BDP Gel and Vehicle In Plaque Psoriasis Subjects

NCT07357831 · Status: RECRUITING · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 537

Last updated 2026-01-27

No results posted yet for this study

Summary

This is a multi-center, randomized, investigator-blinded, calcipotriol and betamethasone dipropionate gel and vehicle-controlled phase 3 clinical study to evaluate the efficacy and safety of MC2-01 cream in the treatment of Chinese plaque psoriasis to assess the efficacy and safety of MC2-01 cream in Chinese subjects aged ≥ 18 years with plaque psoriasis. This study includes a screening period, a treatment period, and a safety follow-up period.

Conditions

Interventions

DRUG

MC2-01 cream

MC2-01 (calcipotriene/betamethasone dipropionate, w/w 0.005%/0.064%) cream

DRUG

MC2-01 vehicle

Vehicle Cream

DRUG

CAL/BDP Gel

calcipotriene/betamethasone dipropionate, w/w 0.005%/0.064%

Sponsors & Collaborators

  • MC2 Therapeutics

    collaborator INDUSTRY

  • Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-12-26
Primary Completion
2026-10-10
Completion
2026-12-17

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07357831 on ClinicalTrials.gov